<DOC>
	<DOCNO>NCT00070239</DOCNO>
	<brief_summary>This phase I trial study side effect best dose alvocidib treat patient metastatic unresectable refractory solid tumor hematologic malignancy . Drugs use chemotherapy , alvocidib , work different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Alvocidib Treating Patients With Metastatic Unresectable Refractory Solid Tumors Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine maximum tolerate dose flavopiridol patient metastatic unresectable refractory solid tumor hematologic malignancy . ( Accrual patient hematologic malignancy temporarily close 11/30/04 ) SECONDARY OBJECTIVES : I . Determine safety profile toxic effect drug patient . II . Determine pharmacokinetics drug patient . III . Determine , pharmacodynamic assay , ability drug inhibit cyclin-dependent kinase activity tumor tissue , normal proliferate tissue , circulate tumor cell , plasma patient . IV . Determine , preliminarily , antitumor activity drug patient . OUTLINE : This 2-part , dose-escalation , multicenter study . PART 1 ( close accrual 8/2005 ) : Patients receive alvocidib IV 1 hour day 1 , 8 , 15 . Cohorts 3-6 patient receive escalate dos alvocidib maximum tolerate dose ( MTD ) * determine . PART 2 : Patients receive alvocidib IV 1 hour MTD determine part 1 receive maintenance dose alvocidib IV 1-6 hour day 1 , 8 , 15 . Cohorts 3-6 patient receive escalate duration maintenance dose alvocidib MTD* determine . An additional cohort 10-20 patient receive alvocidib 1 hour day 1 15 MTD . NOTE : *The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . In part , course repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 1 month every 2 month thereafter .</detailed_description>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Histologically confirm malignancy , include follow type : Hematologic malignancy , include follow : ( Accrual patient hematologic malignancy temporarily close 11/30/04 ) Mantle cell lymphoma Morphologically confirm disease CD20 CD5 positive Any refractory lymphoma Chronic lymphocytic leukemia Rai stage III IV meeting least 1 follow criterion active disease : Weight loss &gt; 10 % last 6 month Fatigue Fever night sweat evidence infection Progressive anemia thrombocytopenia Progressive lymphocytosis lymphocyte double time &lt; 6 month Marked hypogammaglobulinemia paraproteinemia Progressive splenomegaly and/or lymphadenopathy Multiple myeloma Disease confirm bone marrow aspirate and/or biopsy Relapsed refractory disease recent treatment regimen Quantifiable monoclonal immunoglobulin serum and/or urine Solid tumor , include limited following : Breast cancer Histologically cytologically confirm stage IV invasive disease HER2 positivity require study enrollment Tumor overexpressing HER2 confirm immunohistochemistry OR fluorescence situ hybridization Small cell lung cancer Extensive stage limit stage disease relapse Extrapulmonary small cell carcinoma allow Squamous cell carcinoma head neck Metastatic , recurrent , refractory disease Renal cell carcinoma Mesothelioma Pleural peritoneal disease epithelial , sarcomatoid , mixed subtype Melanoma Kaposi 's sarcoma Metastatic unresectable disease standard therapy exist longer effective Measurable nonmeasurable disease ( solid tumor patient ) Measurable disease define least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique 10 mm spiral CT scan Nonmeasurable disease include follow : All lesion , include lesion &lt; 20 mm conventional technique 10 mm spiral CT scan Bone lesion Cytologically positive pleural peritoneal disease Elevated tumor marker ( e.g. , CEA , CA 125 , CA 199 , tumor marker ) Multinodular confluent nonmeasurable pulmonary , hepatic , adrenal , intraabdominal , skin metastasis Previously treat least 1 chemotherapy regimen* Prior therapy may include combined modality treatment ( e.g. , fulldose chemotherapy radiotherapy radiosensitizing chemotherapy ) Prior therapy flavopiridol allow provided patient enrol flavopiridol clinical trial employ different schedule NOTE : *Except case chemotherapy know effective ( e.g. , renal cell carcinoma , chondrosarcoma , gastrointestinal stromal tumor ) No active CNS metastases History CNS metastases allow provide follow criterion meet : Previously treat stable asymptomatic least 4 week since completion treatment Image documentation require Off steroid stable dose steroid least 1 week Hormone receptor status : Not specify Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy More 12 week Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Platelet count &gt; 75,000/mm^3 ( 50,000 hematologic malignancy ) * ( Accrual patient hematologic malignancy temporarily close 11/30/04 ) NOTE : *Unless abnormality cause tumor burden cumulative prior chemotherapy Hepatic Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal Creatinine ≤ 2.0 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular No myocardial infarction within past 6 month No unstable angina within past 6 month No transient ischemic attack cerebrovascular accident within past 6 month No history arterial vascular event No new cardiac arrhythmia likely related cardiac ischemia within past 6 month No symptomatic congestive heart failure Pulmonary No history pulmonary embolism within past 6 month Gastrointestinal No chronic diarrheal disease within past 6 month No severe malnutrition No intractable emesis Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective hormonal barrier contraception No ongoing active infection No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) At least 3 week since prior radiotherapy No prior radiotherapy 50 % bone marrow Recovered prior therapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>